Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Erythropoietin for Anemia in Lymphoma
NCT04910594Phase 3Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2021
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of erythropoietin in anemia, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Hemoglobin response rate of subjects during treatment at 20 weeks. Status: unknown.
02
Drugs
erythropoietin
03
Conditions
anemia
Beyond the preview
Go deeper on NCT04910594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910594.